$HALB JACKSON CENTER, PA / ACCESSWIRE / December 23, 2020 / Halberd Corp. (OTC PINK:HALB) research has produced a second monoclonal antibody (mAb) against the Covid-19 spike protein. Initial testing displays a stronger affinity for the SARS-CoV-2 antigen than Halberd's initial antibody. Testing continues through the holidays on each antibody to establish potency and specificity (i.e., targets only the SARS-CoV-2 antigen) as well as a potential "cocktail mix" of both antibodies acting in concert.

https://www.wsj.com/articles/halberd-corporat...66?tesla=y